PAHC Form 4 reports acquisition/exercise transactions

David Glenn reported acquisition or exercise transactions in a Form 4 filing for PAHC.

Rhea-AI Filing Summary

David Glenn reported acquisition or exercise transactions in a Form 4 filing for PAHC. The filing lists transactions totaling 72,528 shares at a weighted average price of $51.63 per share. Following the reported transactions, holdings were 240,000 shares.

Insider Trade Summary

30,000 shares exercised/converted

Exercise 3 txns

Insider David Glenn

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Other	Class A Common Stock	12,528	$51.625	$647K
Exercise	Restricted Stock Units	30,000	$0.00	$0.00
Exercise	Class A Common Stock	30,000	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 240,000 contracts (Direct); Class A Common Stock — 52,317 shares (Direct)

Footnotes (5)

1. F1. Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock.
2. F2. Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of the RSUs.
3. F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.54 to $52.03. The reporting person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").
5. F5. Pursuant to the Award Agreement, (i) 150,000 RSUs are subject to time vesting (collectively, the "Time Vesting RSUs") and vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs are subject to performance vesting (collectively, the "Performance Vesting RSUs") and vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Issuer's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PAHC CFO Glenn David report on this Form 4?

Glenn David reported exercising 30,000 restricted stock units into Class A Common Stock and a related sale of 12,528 shares. The sale was a broker-assisted cashless transaction to cover tax withholding tied to the RSU vesting and settlement.

How many PAHC shares does the CFO directly own after these transactions?

After the reported transactions, the CFO directly owns 52,317 shares of Phibro Animal Health Class A Common Stock. This reflects receipt of 30,000 shares from RSU settlement and the sale of 12,528 shares to satisfy associated tax obligations.

At what price were the 12,528 PAHC shares sold to cover taxes?

The 12,528 shares were sold at a weighted average price of $51.625 per share. The filing notes the shares were sold in multiple trades between $51.54 and $52.03 as part of a broker-assisted cashless exercise for tax withholding.

How many restricted stock units does the PAHC CFO hold after the Form 4 transactions?

Following the transactions, the CFO beneficially owns 240,000 restricted stock units. These RSUs were granted on February 9, 2024 under the company’s incentive plan and remain outstanding subject to time-based and performance-based vesting conditions.

What are the vesting terms for the 300,000 PAHC RSUs granted in 2024?

The 300,000 RSUs granted February 9, 2024 are split evenly: 150,000 time-vesting units vest in five equal annual installments, and 150,000 performance-vesting units depend on the average stock price over a 90-day period five years after grant, with certain earlier vesting upon qualifying terminations.

Why is the Form 4 transaction code J used for part of the PAHC CFO’s activity?

Transaction code J reflects an “other” type of transaction, here covering the broker-assisted cashless sale of 12,528 shares. The filing explains that these shares were sold specifically to satisfy tax withholding obligations from the vesting and settlement of restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 04:15 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

David Glenn

(Last) (First) (Middle)

300 FRANK W. BURR BLVD., STE 21

(Street)

TEANECK NJ 07666

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PHIBRO ANIMAL HEALTH CORP [ PAHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/09/2026		M		30,000	A	(1)	64,845	D
Class A Common Stock	02/11/2026		J		12,528(2)	D	$51.625(3)	52,317	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/09/2026		M			30,000	(4)(5)	(4)(5)	Class A Common Stock	30,000	$0	240,000	D

Explanation of Responses:

1. Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock.

2. Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of the RSUs.

3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.54 to $52.03. The reporting person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").

5. Pursuant to the Award Agreement, (i) 150,000 RSUs are subject to time vesting (collectively, the "Time Vesting RSUs") and vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs are subject to performance vesting (collectively, the "Performance Vesting RSUs") and vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Issuer's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.

	/s/ Judith Weinstein, as Attorney-in-Fact for Glenn David	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.